- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Catalyst Pharmaceuticals Inc (CPRX)
Catalyst Pharmaceuticals Inc stock price live, this page displays NASDAQ CPRX stock exchange data. View the CPRX premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Catalyst Pharmaceuticals Inc real time stock price chart below.
What Is the Catalyst Pharmaceuticals Inc Stock Price Today?
The Catalyst Pharmaceuticals Inc stock price today is 19.680.
What Is the Stock Symbol for Catalyst Pharmaceuticals Inc?
The stock symbol for Catalyst Pharmaceuticals Inc is ""CPRX.""
What Stock Exchange Does Catalyst Pharmaceuticals Inc Trade On?
Catalyst Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is Catalyst Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Catalyst Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the CPRX quote. (ISIN: US14888U1016)
What Is the Catalyst Pharmaceuticals Inc Stock Price Today?
The Catalyst Pharmaceuticals Inc stock price today is 19.680.
What Is the Stock Symbol for Catalyst Pharmaceuticals Inc?
The stock symbol for Catalyst Pharmaceuticals Inc is ""CPRX.""
What Stock Exchange Does Catalyst Pharmaceuticals Inc Trade On?
Catalyst Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is Catalyst Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Catalyst Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the CPRX quote. (ISIN: US14888U1016)
Fair Value
An estimate of a Catalyst Pharmaceuticals's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
19.360
19.981
52 wk Range
19.000
26.580
CPRX Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
CPRX is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a Catalyst Pharmaceuticals's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
19.36019.981
52 wk Range
19.00026.580
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
CPRX Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Catalyst Pharmaceuticals's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
34.286
Upside
+74.22%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
3 analysts have revised their earnings downwards for the upcoming period
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Sell
Moving Averages
Sell
Catalyst Pharmaceuticals Inc Company Profile
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States. It offers Firdapse for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); Fycompa, a novel non-competitive selective antagonist at the postsynaptic ionotropic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate receptor that is used to treat focal onset seizures, as well as tonic-clonic seizures; Ruzurgi for the treatment of pediatric LEMS patients; and AGAMREE, a corticosteroid for the treatment of duchenne muscular dystrophy. The company has license agreements with BioMarin Pharmaceutical Inc.; and a collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
Catalyst Pharmaceuticals Inc Earnings Call Summary for Q2/2025
- Q2 2025 EPS of $0.68 beats $0.39 forecast; revenue of $146.54M surpasses $140.22M estimate
- Revenue up 19.4% YoY; GammaRy sales surge 213%; full-year guidance set at $545M-$565M
- Stock falls 7.66% despite earnings beat; InvestingPro suggests undervaluation at P/E of 12.4
- Strong cash position of $652.8M; focus on expanding Firdapse oncology market and business development
- CEO highlights strategic growth focus; CCO expects sustained growth into 2026 and beyond
Last Updated: 07/08/2025, 18:22
Read Full TranscriptCompare CPRX to Peers and Sector
Metrics to compare | CPRX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCPRXPeersSector | |
|---|---|---|---|---|
P/E Ratio | 11.5x | −1.1x | −0.5x | |
PEG Ratio | 0.06 | −0.04 | 0.00 | |
Price/Book | 2.8x | 2.5x | 2.6x | |
Price / LTM Sales | 4.3x | 8.2x | 3.3x | |
Upside (Analyst Target) | 72.7% | 322.3% | 42.9% | |
Fair Value Upside | Unlock | 23.7% | 6.2% | Unlock |
Analyst Ratings
7 Buy
0 Hold
0 Sell
Ratings:
7 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 34.286
(+74.22% Upside)
Earnings
Latest Release
Aug 06, 2025
EPS / Forecast
0.68 / 0.39
Revenue / Forecast
146.54M / 140.22M
People Also Watch
FAQ
What Stock Exchange Does Catalyst Pharmaceuticals Trade On?
Catalyst Pharmaceuticals is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Catalyst Pharmaceuticals?
The stock symbol for Catalyst Pharmaceuticals is "CPRX."
What Is the Catalyst Pharmaceuticals Market Cap?
As of today, Catalyst Pharmaceuticals market cap is 2.41B.
What Is Catalyst Pharmaceuticals's Earnings Per Share (TTM)?
The Catalyst Pharmaceuticals EPS (TTM) is 1.73.
When Is the Next Catalyst Pharmaceuticals Earnings Date?
Catalyst Pharmaceuticals will release its next earnings report on 04 Nov 2025.
From a Technical Analysis Perspective, Is CPRX a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Catalyst Pharmaceuticals Stock Split?
Catalyst Pharmaceuticals has split 0 times.
How Many Employees Does Catalyst Pharmaceuticals Have?
Catalyst Pharmaceuticals has 181 employees.
What is the current trading status of Catalyst Pharmaceuticals (CPRX)?
As of 12 Aug 2025, Catalyst Pharmaceuticals (CPRX) is trading at a price of 19.68, with a previous close of 19.68. The stock has fluctuated within a day range of 19.36 to 19.98, while its 52-week range spans from 19.00 to 26.58.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.